The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the agency since 1998.
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which she experienced when taking opioids.
The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.
FRIDAY, Jan. 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain ...
Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, Intel edges higher ...